HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on Acelyrin (NASDAQ:SLRN) and maintained a $30 price target.
September 12, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Acelyrin (NASDAQ:SLRN) and maintained a $30 price target.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Acelyrin. The maintained price target of $30 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100